Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs SHASUN PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON SHASUN PHARMA BIOCON /
SHASUN PHARMA
 
P/E (TTM) x 35.5 123.9 28.6% View Chart
P/BV x 4.5 8.5 52.7% View Chart
Dividend Yield % 0.2 0.2 93.9%  

Financials

 BIOCON    SHASUN PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
SHASUN PHARMA
Mar-14
BIOCON /
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs70794 750.8%   
Low Rs55446 1,214.5%   
Sales per share (Unadj.) Rs91.9214.2 42.9%  
Earnings per share (Unadj.) Rs16.75.3 313.2%  
Cash flow per share (Unadj.) Rs24.215.8 152.8%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.21.4 11.1%  
Book value per share (Unadj.) Rs101.653.3 190.5%  
Shares outstanding (eoy) m600.0056.62 1,059.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.90.3 2,102.2%   
Avg P/E ratio x37.713.1 288.1%  
P/CF ratio (eoy) x26.14.4 590.3%  
Price / Book Value ratio x6.21.3 473.4%  
Dividend payout %6.018.7 31.9%   
Avg Mkt Cap Rs m378,3303,958 9,559.2%   
No. of employees `0006.1NA-   
Total wages/salary Rs m11,6532,164 538.6%   
Avg. sales/employee Rs Th8,994.3NM-  
Avg. wages/employee Rs Th1,900.7NM-  
Avg. net profit/employee Rs Th1,635.3NM-  
INCOME DATA
Net Sales Rs m55,14412,127 454.7%  
Other income Rs m1,444229 629.6%   
Total revenues Rs m56,58812,356 458.0%   
Gross profit Rs m15,8831,009 1,574.1%  
Depreciation Rs m4,478594 754.4%   
Interest Rs m709415 170.8%   
Profit before tax Rs m12,140230 5,285.2%   
Minority Interest Rs m90-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123-73 -2,919.4%   
Profit after tax Rs m10,026302 3,318.5%  
Gross profit margin %28.88.3 346.2%  
Effective tax rate %17.5-31.7 -55.2%   
Net profit margin %18.22.5 729.8%  
BALANCE SHEET DATA
Current assets Rs m48,2286,884 700.5%   
Current liabilities Rs m30,3768,456 359.2%   
Net working cap to sales %32.4-13.0 -249.8%  
Current ratio x1.60.8 195.0%  
Inventory Days Days6862 110.8%  
Debtors Days Days86108 79.5%  
Net fixed assets Rs m64,1304,970 1,290.3%   
Share capital Rs m3,000113 2,647.8%   
"Free" reserves Rs m57,9802,875 2,016.8%   
Net worth Rs m60,9803,020 2,019.1%   
Long term debt Rs m15,7661,817 867.5%   
Total assets Rs m121,92413,347 913.5%  
Interest coverage x18.11.6 1,166.7%   
Debt to equity ratio x0.30.6 43.0%  
Sales to assets ratio x0.50.9 49.8%   
Return on assets %8.85.4 163.8%  
Return on equity %16.410.0 164.4%  
Return on capital %16.813.3 125.8%  
Exports to sales %28.146.4 60.7%   
Imports to sales %18.914.2 132.4%   
Exports (fob) Rs m15,5065,622 275.8%   
Imports (cif) Rs m10,3991,728 601.9%   
Fx inflow Rs m15,5065,843 265.4%   
Fx outflow Rs m10,3992,173 478.5%   
Net fx Rs m5,1073,669 139.2%   
CASH FLOW
From Operations Rs m11,546398 2,903.9%  
From Investments Rs m-7,138-1,635 436.6%  
From Financial Activity Rs m-2,4171,309 -184.7%  
Net Cashflow Rs m2,10371 2,953.7%  

Share Holding

Indian Promoters % 40.4 39.2 103.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 3.6 233.3%  
FIIs % 10.7 17.6 60.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 39.6 50.3%  
Shareholders   109,995 20,750 530.1%  
Pledged promoter(s) holding % 0.0 12.3 0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare BIOCON With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 15, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS